CONFERENCE PROGRAM

Saturday, January 11

4:30 p.m.-6:15 p.m.  PLENARY SESSION 1: THERAPEUTIC TARGETING AND VULNERABILITIES OF RAS-DRIVEN LUNG CANCER
Pacific Ballroom 23-24

4:30 p.m.–4:55 p.m.  Title to be announced
Ferdinandos Skoulidis, The University of Texas MD Anderson Cancer Center, Houston, TX

4:55 p.m.–5:20 p.m.  Insights into KRAS biology to identify potential therapeutic strategies
Chiara Ambrogio, Dana-Farber Cancer Institute, Boston, MA

5:20 p.m.–5:45 p.m.  Therapeutic approaches in KRAS-driven non-small cell lung cancer
Caroline McCoach, UCSF School of Medicine, San Francisco, CA

5:45 p.m.–6:00 p.m.  Transcriptional subtypes resolve tumor heterogeneity and identify therapeutic vulnerabilities in lung cancer*
Jonathan Cooper, Genentech, Inc., South San Francisco, CA

6:00 p.m.–6:15 p.m.  The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: Preliminary evaluation of a first-in-man phase 1 clinical trial*
Sai-Hong Ignatius Ou, University of California Irvine, Irvine, CA

6:15 p.m.–6:30 p.m.  BREAK
Pacific Ballroom Pre-Function Area 23-26

6:30 p.m.–7:30 p.m.  WELCOME REMARKS AND OPENING KEYNOTE
Pacific Ballroom 23-24

Welcome Remarks
Chandra P. Belani, Chief Scientific Officer, International Association for the Study of Lung Cancer

Early-stage drug development in the 21st century
William Pao, Roche Innovation Center Basel, Basel, Switzerland
(not eligible for CME credit)

7:30 p.m.–9:30 p.m.  OPENING RECEPTION
Pacific Ballroom 25/26

*Short talk from proffered abstract
CONFERENCE PROGRAM

Sunday, January 12

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST
Pacific Ballroom 25/26

8:00 a.m.-9:30 a.m.  PLENARY SESSION 2: LUNG PRENEOPLASIA AND EARLY DETECTION
Pacific Ballroom 23-24
8:00 a.m.-8:25 a.m.  Genomic underpinnings of tumor behavior in in situ and early lung adenocarcinoma
Pierre Massion, Vanderbilt-Ingram Cancer Center, Nashville, TN
8:25 a.m.-8:50 a.m.  Intercepting lung cancer by understanding premalignant changes in the airway field
Jennifer E. Beane, Boston University School of Medicine, Boston, MA
8:50 a.m.-9:15 a.m.  Plasma proteomic, glycomic, and autoantibody biomarkers for lung cancer early detection
Paul D. Lampe, Fred Hutchinson Cancer Research Center, Seattle, WA
9:15 a.m.-9:30 a.m.  The genome-wide mutational landscape of lung cancer in never-smokers: The Women’s Health Initiative (WHI) cohort*
Sitapriya Moorthi, Fred Hutchinson Cancer Research Center, Seattle, WA

9:30 a.m.-10:00 a.m.  BREAK
Pacific Ballroom Pre-Function Area 23-26

10:00 a.m.-11:30 a.m.  PLENARY SESSION 3: METABOLISM
Pacific Ballroom 23-24
10:00 a.m.-10:25 a.m.  Mapping mitochondrial heterogeneity in lung cancer
David B. Shackelford, UCLA David Geffen School of Medicine, Los Angeles, CA
10:25 a.m.-10:50 a.m.  Identification of new therapeutic targets in non-small cell lung cancer
Kathryn A. O’Donnell, UT Southwestern Medical Center, Dallas, TX
10:50 a.m.-11:15 a.m.  Novel metabolic functions for redox regulators in non-small cell lung cancer
Gina M. DeNicola, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
11:15 a.m.-11:30 a.m.  Integrated proteometabolomic analysis reveals metabolic vulnerabilities in small-cell lung cancer*
Antony Prabhu, H. Lee Moffitt Cancer Center, Tampa, FL

*Short talk from proffered abstract
11:35 a.m.  POSTER SESSION A HIGHLIGHTS
Pacific Ballroom 25/26

Presenters will give a 2-minute, 1-slide teaser preview of their posters to be presented in Poster Session A.

(not eligible for CME credit)

(A03) Lung adenocarcinoma resident microbiome may contribute to cancer hypomethylation status
Erin Marshall, BC Cancer Research Centre, Vancouver, BC, Canada

(A05) ART1, a mono-ADP-ribosyltransferase, regulates tumor-infiltrating CD8+ T cells and is highly expressed in EGFR mutated lung cancers
Sumit Mukherjee, Weill Cornell Medicine, New York, NY

(A06) Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in preclinical models of NSCLC
Robert Nichols, Revolution Medicines, Redwood City, CA

(A07) The genomic landscape of SMARCA4 alterations and association with patient outcomes in lung cancer
Adam Schoenfeld, Memorial Sloan Kettering Cancer Center, New York, NY

(A08) MYC-driven SCLC has unique metabolic vulnerabilities
Sarah Wait, Huntsman Cancer Institute, Salt Lake City, UT

12:00 p.m.-2:00 p.m.  POSTER SESSION A / LUNCH
Pacific Ballroom 25/26

2:00 p.m.-4:00 p.m.  PLENARY SESSION 4: PRECISION IMMUNOTHERAPY
Pacific Ballroom 23-24

2:00 p.m.-2:25 p.m.  Role of the tumor microenvironment in sensitivity and resistance to immunostimulatory therapies in NSCLC
Kurt A. Schalper, Yale University, New Haven, CT

2:25 p.m.-2:50 p.m.  Liquid biopsy approaches for precision immuno-oncology
Valsamo K. Anagnostou, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD

2:50 p.m.-3:15 p.m.  Targeting myeloid cells that define the tumor immune microenvironment in NSCLC
Thomas U. Marron, Mt. Sinai Medical Center Tisch Cancer Institute, New York, NY
CONFERENCE PROGRAM

3:15 p.m.-3:40 p.m.  Preclinical and translational approaches to capturing mechanisms of immunotherapy response and resistance in NSCLC
   Don L. Gibbons, The University of Texas MD Anderson Cancer Center, Houston, TX

3:40 p.m.-3:55 p.m.  A reservoir of tumor-specific CD8 T cells in lung cancer resides in the draining lymph node*
   Nikhil Joshi, Yale University, New Haven, CT

4:00 p.m.-4:15 p.m.  BREAK
   Pacific Ballroom Pre-Function Area 23-26

4:15 p.m.-6:00 p.m.  PLENARY SESSION 5: TARGETING TUMOR SUPPRESSORS AND “UNDRUGGABLE” TARGETS
   Pacific Ballroom 23-24

4:15 p.m.-4:40 p.m.  Decoding critical targets of LKB1/STK11 in NSCLC
   Reuben J. Shaw, Salk Institute, La Jolla, CA

4:40 p.m.-5:05 p.m.  A new generation of anti-Myc mini-proteins as potential therapy for NSCLC
   Laura Soucek, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

5:05 p.m.-5:30 p.m.  Druggable vulnerabilities in therapy-resistant lung cancers
   Kris C. Wood, Duke University, Durham, NC

5:30 p.m.-5:45 p.m.  Blockade of myeloid suppressor cells overcomes the anti-PD-1/PD-L1 resistance in KRAS-driven and LKB1-deficient NSCLC*
   Rui Li, University of California Los Angeles, Los Angeles, CA

5:45 p.m.-6:00 p.m.  Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma*
   Michael Gillette, Broad Institute of MIT and Harvard, Cambridge, MA

*Short talk from proffered abstract
Monday, January 13

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST
Pacific Ballroom 25/26

8:00 a.m.-9:30 a.m.  PLENARY SESSION 6: CELLULAR THERAPIES, VACCINES, AND NEW IO MODALITIES
Pacific Ballroom 23-24
8:00 a.m.-8:25 a.m.  A new world for lung cancer vaccines: Beyond picking a single antigen for everyone
Edward B. Garon, University of California (UCLA), Los Angeles, CA
8:25 a.m.-8:50 a.m.  Evaluating the role of B cells and tertiary lymphoid structures in lung cancer development and progression
Tullia C. Bruno, University of Pittsburgh School of Medicine, Pittsburgh, PA
8:50 a.m.-9:05 a.m.  Dendritic cell in situ vaccination potentiates anti-PD-1 efficacy and induces immunoediting in a murine model of NSCLC*
Ramin Salehi-Rad, University of California Los Angeles, Los Angeles, CA
9:05 a.m.-9:20 a.m.  N-803 plus nivolumab for advanced or metastatic non-small cell lung cancer: Update on phase II experience of combination PD1 blockade with an IL-15 superagonist*
John Wrangle, Medical University of South Carolina, Charleston, SC

9:30 a.m.-10:00 a.m.  BREAK
Pacific Ballroom Pre-Function Area 23-26

10:00 a.m.-12:20 p.m.  PLENARY SESSION 7: SMALL-CELL LUNG CANCER
Pacific Ballroom 23-24
10:00 a.m.-10:25 a.m.  Pan-cancer convergence to a small-cell neuroendocrine phenotype that shares susceptibilities with hematologic malignancies
Thomas G. Graeber, University of California Los Angeles, Los Angeles, CA
10:25 a.m.-10:50 a.m.  ASCL1 represses a latent osteogenic program in small-cell lung cancer arising from multiple cells of origin
Trudy G. Oliver, University of Utah Huntsman Cancer Institute, Salt Lake City, UT
10:50 a.m.-11:15 a.m.  Identifying chemically tractable vulnerabilities in small-cell lung cancer
David G. McFadden, UT Southwestern Medical Center, Dallas, TX
11:15 a.m.-11:40 a.m.  Developing new therapies in small-cell lung cancer using parallel clinical and laboratory-based studies
Anna Farago, Massachusetts General Hospital, Boston, MA

*Short talk from proffered abstract
CONFERENCE PROGRAM

11:40 a.m.-12:05 p.m.  Targeting DLL3 in small-cell lung cancer with novel modalities
John T. Poirier, Perlmutter Cancer Center at NYU Langone Health, New York, NY

12:05 p.m.-12:20 p.m.  Unraveling the mechanisms of small-cell lung cancer brain metastasis*
Fangfei Qu, Stanford University School of Medicine, Stanford, CA

12:20 p.m.-2:00 p.m.  LUNCH ON OWN

2:00 p.m.-3:15 p.m.  PLENARY SESSION 8: METASTASIS AND TUMOR PROGRESSION
Pacific Ballroom 23-24
2:00 p.m.-2:25 p.m.  Adaptive determinants of metastatic progression in lung adenocarcinoma
Don X. Nguyen, Yale University School of Medicine, New Haven, CT
2:25 p.m.-2:50 p.m.  Stage-specific roles of RB constrain tumor progression, lineage fidelity, and metastasis
David Feldser, University of Pennsylvania, Philadelphia, PA
2:50 p.m.-3:15 p.m.  Restoring Capicua (CIC) expression to limit lung cancer metastasis
Ross A. Okimoto, University of California San Francisco, San Francisco, CA

3:20 p.m.-4:50 p.m.  Panel Discussion: What to Do about Squamous Cell?
Pacific Ballroom 23-24
Panel Moderator: Trudy G. Oliver, University of Utah Huntsman Cancer Institute, Salt Lake City, UT
Panelists:
Eric B. Haura, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Trudy G. Oliver
Paul Paik, Memorial Sloan Kettering Cancer Center, New York, NY
Kwok-Kin Wong, New York University Langone Medical Center, New York, NY

Targeting glucose reliance in lung squamous cell carcinoma*
Jung-whan Kim, University of Texas at Dallas, Richardson, TX

4:55 p.m.  POSTER SESSION B HIGHLIGHTS
Pacific Ballroom 25/26

Presenters will give a 2-minute, 1-slide teaser preview of their posters to be presented in Poster Session B.

(not eligible for CME credit)

(B01)  Active YAP as a functional marker of drug-tolerant persister cells in EGFR-mutant and ALK fusion-positive NSCLC
Franziska Haderk, University of California San Francisco, San Francisco, CA

*Short talk from proffered abstract
The GSK3 signaling axis regulates adaptive glutamine metabolism in lung squamous cell carcinoma
Milica Momcilovic, University of California Los Angeles, Los Angeles, CA

JNJ-61186372, an Fc effector enhanced EGFR/cMet bispecific antibody, induces EGFR/cMet downmodulation and efficacy through monocyte and macrophage trogocytosis
Sheri Moores, Janssen Research & Development, Spring House, PA

Integrative approach to map the tumor suppressor landscape of small-cell lung cancer genome
Kwon-Sik Park, University of Virginia, Charlottesville, VA

Identifying SCLC vulnerabilities using phenotypic chemical screens
Juan Manuel Povedano Selfa, University of Texas Southwestern Medical Center, Dallas, TX

Time-resolved RNA-seq identifies transient gene expression changes following initial chemotherapy challenge in small-cell lung cancer
David Shia, University of California Los Angeles, Los Angeles, CA

Mechanisms of alectinib resistance in a leptomeningeal carcinomatosis of EML4-ALK lung cancer and its circumvention by EGR-TKIs
Seiji Yano, Kanazawa University, Kanazawa, Ishikawa, Japan

5:15 p.m.-7:15 p.m. POSTER SESSION B / RECEPTION
Pacific Ballroom 25/26

Tuesday, January 14

7:00 a.m.-8:00 a.m. CONTINENTAL BREAKFAST
Pacific Ballroom 25/26

8:00 a.m.-10:00 a.m. PLENARY SESSION 9: GENOMIC MECHANISMS OF RESISTANCE
Pacific Ballroom 23-24

8:00 a.m.-8:25 a.m. Title to be announced
Robert C. Doebele, University of Colorado Denver, Aurora, CO

8:25 a.m.-8:50 a.m. Title to be announced
Zofia Piotrowska, Massachusetts General Hospital, Boston, MA
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:50 a.m.-9:15 a.m.</td>
<td>Investigating and overcoming primary resistance of EGFR and HER2 (ERBB2) exon 20 mutant NSCLC</td>
<td>Jacquelyne Robichaux, The University of Texas MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>9:15 a.m.-9:35 a.m.</td>
<td>Genetic contributors to tumor progression and drug resistance in EGFR mutant lung cancer</td>
<td>Katerina A. Politi, Yale Cancer Center, New Haven, CT</td>
</tr>
<tr>
<td>9:35 a.m.-9:45 a.m.</td>
<td>Advocate presentation</td>
<td>Jill Feldman, Co-Founder, EGFR Resisters</td>
</tr>
<tr>
<td>9:45 a.m.-9:55 a.m.</td>
<td>Advocate presentation</td>
<td>Janet Freeman-Daily, Co-Founder, The ROS1ders</td>
</tr>
<tr>
<td>10:00 a.m.-10:30 a.m.</td>
<td>BREAK</td>
<td>Pacific Ballroom Pre-Function Area 23-26</td>
</tr>
<tr>
<td>10:30 a.m.-12:15 p.m.</td>
<td>PLENARY SESSION 10: NONGENETIC MECHANISMS OF RESISTANCE</td>
<td>Pacific Ballroom 23-24</td>
</tr>
<tr>
<td>10:30 a.m.-10:55 a.m.</td>
<td>Nongenetic mechanisms of resistance</td>
<td>Trever G. Bivona, University of California San Francisco, San Francisco, CA</td>
</tr>
<tr>
<td>10:55 a.m.-11:20 a.m.</td>
<td>Mechanisms of small-cell lineage transformation in resistance to targeted therapies</td>
<td>William W. Lockwood, British Columbia Cancer Agency, Vancouver, BC, Canada</td>
</tr>
<tr>
<td>11:20 a.m.-11:45 a.m.</td>
<td>The YAP/FOXM1 axis regulates EMT-associated EGFR tyrosine kinase inhibitor resistance and increased expression of spindle assembly checkpoint components</td>
<td>John V. Heymach, The University of Texas MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>11:45 a.m.-12:05 p.m.</td>
<td>Bypass signaling pathways that confer resistance to EGFR and ALK inhibitors</td>
<td>Christine M. Lovly, Vanderbilt University School of Medicine, Nashville, TN</td>
</tr>
<tr>
<td>12:05 p.m.-12:15 p.m.</td>
<td>Advocate presentation</td>
<td>Colin Barton, Executive Board Member, ALK Positive</td>
</tr>
</tbody>
</table>